You have 9 free searches left this month | for more free features.

CAR-T Therapy

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Gastric Cancer, Colon Cancer, Pancreas Cancer Trial in Nanchang (CEA CAR-T cells)

Recruiting
  • Gastric Cancer
  • +6 more
  • CEA CAR-T cells
  • Nanchang, Jiangxi, China
    The First Affiliated Hospital of Nanchang University
Aug 23, 2023

B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Azacitidine Injection
  • +2 more
  • (no location specified)
Oct 15, 2023

B-cell Acute Lymphocytic Leukemia Trial in Suzhou (CD19 CAR-T cells)

Recruiting
  • B-cell Acute Lymphocytic Leukemia
  • CD19 CAR-T cells
  • Suzhou, China
    The First Affiliated Hospital of Soochow University
Jan 11, 2023

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

Mesothelin-positive Advanced Malignant Solid Tumors Trial (Anti-mesothelin CAR-T cells)

Not yet recruiting
  • Mesothelin-positive Advanced Malignant Solid Tumors
  • Anti-mesothelin CAR-T cells
  • (no location specified)
Mar 13, 2023

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023

Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial in Zhengzhou (ThisCART19A, Fludarabine Pill, Cyclophosphamide)

Not yet recruiting
  • Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
  • Zhengzhou, Henan, China
    Henan cancer hospital
Nov 28, 2022

Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • GC012F
  • (no location specified)
Apr 28, 2023

B-Cell Non-Hodgkin Lymphoma, Multiple Myeloma Trial in Duarte (Best Practice, Cognitive Intervention, Comprehensive Geriatric

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • Multiple Myeloma
  • Best Practice
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Sep 19, 2023

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Non Hodgkin Lymphoma Trial in San Francisco (Neuropsychological testing)

Not yet recruiting
  • Non Hodgkin Lymphoma
  • Neuropsychological testing
  • San Francisco, California
    Stanford Cancer Center
Nov 9, 2022

Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T, VRD-based regimen)

Recruiting
  • Plasma Cell Leukemia
  • anti-BCMA CAR-T
  • VRD-based regimen
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
Aug 4, 2023

Digestive Tumor Trial (TM4SF1-positive chimeric antigen receptor T-cell therapy)

Not yet recruiting
  • Digestive Tumor
  • TM4SF1-positive chimeric antigen receptor T-cell therapy
  • (no location specified)
Dec 21, 2022

Gastric Cancer, Pancreatic Cancer, Solid Tumor Trial in Beijing (KD-496)

Not yet recruiting
  • Gastric Cancer
  • +2 more
  • KD-496
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 15, 2023

Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T, VRD)

Recruiting
  • Multiple Myeloma
  • anti-BCMA CAR-T
  • VRD
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 5, 2023

Solid Tumor, Lung Cancer, Colorectal Cancer Trial in Chongqing (CEA CAR-T cells)

Recruiting
  • Solid Tumor
  • +6 more
  • CEA CAR-T cells
  • Chongqing, Chongqing, China
  • +1 more
Sep 9, 2022

Colorectal Cancer, Esophageal Cancer, Stomach Cancer Trial in Jinan (CEA CAR-T cells)

Recruiting
  • Colorectal Cancer
  • +5 more
  • CEA CAR-T cells
  • Jinan, Shandong, China
    The Second People's Hospital of Shandong Province
Jul 19, 2022

Metastatic Tumor, Renal Cell Carcinoma, Advanced Cancer Trial in Jinan (CD70 CAR-T cells)

Recruiting
  • Metastatic Tumor
  • +2 more
  • CD70 CAR-T cells
  • Jinan, Shandong, China
    The Second People's Hospital of Shandong Province
Jun 26, 2022

T-cell Acute Lymphoblastic Leukemia Trial in Beijing (CD5 CAR-T)

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • CD5 CAR-T
  • Beijing, Beijing, China
    Xuanwu Hospital Capital Medical University
Oct 23, 2022

Recurrent DLBCL, Refractory DLBCL Trial in Duarte (procedure, biological, radiation)

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Biospecimen Collection
  • +6 more
  • Duarte, California
    City of Hope Medical Center
Mar 24, 2023

B-cell Non-Hodgkin's Lymphoma Trial in Shanghai (Human CD19Targeted T Cells Injection)

Recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • Human CD19Targeted T Cells Injection
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Jun 29, 2022

Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine

Not yet recruiting
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • Ciltacabtagene Autoleucel
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 2, 2023

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023